Product Name: GSK3a (280-287) pS282+pY284+pY285
Product Number: PE-04AUS01
| Size: | $US |
Peptide Name: GSK3a (280-287) pS282+pY284+pY285
Product Use: This phosphopeptide may be useful as a substrate for screening the phosphatase activity of protein phosphatases. The peptide sequence is located in the protein kinase catalytic domain activation T loop region between subdomains VII and VIII. S282, Y284 and Y285 phosphorylation are predicted to be inhibitory for phosphotransferase activity. These phosphosites are located in the kinase activation loop just before the catalytic subdomain VIII.
Peptide Production Method: Solid-phase peptide synthesis
Peptide Origin: Homo sapiens
Peptide Sequence: IC(pS)R(pY)(pY)RA
Peptide Modifications N Terminus: Free amino
Peptide Modifications C Terminus: Amide
Product Use: This phosphopeptide may be useful as a substrate for screening the phosphatase activity of protein phosphatases. The peptide sequence is located in the protein kinase catalytic domain activation T loop region between subdomains VII and VIII. S282, Y284 and Y285 phosphorylation are predicted to be inhibitory for phosphotransferase activity. These phosphosites are located in the kinase activation loop just before the catalytic subdomain VIII.
Peptide Production Method: Solid-phase peptide synthesis
Peptide Origin: Homo sapiens
Peptide Sequence: IC(pS)R(pY)(pY)RA
Peptide Modifications N Terminus: Free amino
Peptide Modifications C Terminus: Amide
Peptide Modifications Other: Phosphorylated
Storage Conditions: -20°C
Storage Conditions: -20°C
Scientific Background: GSK3a is a protein-serine/threonine kinase of the CMGC group and GSK family. It is highly active following tyrosine phosphorylation within its activation T loop. Phosphorylation at Y279 increases phosphotransferase activity and promotes nuclear localization. Phosphorylation at S21 inhibits phosphotransferase activity. Through direct phosphorylation, it can inactivate glycogen synthase (for insulin regulation), CTNNB1/beta-catenin, APC, and AXIN1. GSK3 has been proposed as a tumour suppressor protein (TSP), since with loss of GSK3 there is an increase in WNT signalling, with a beta-catenin stabilization, leading to tumourigenesis. GSK3 has also been proposed to act as an oncoprotein (OP), as acute leukemia required GSK3 for cell proliferation. In most human cancers, it is up-regulated in expression about 1.6-times the rate observed for most protein kinases.
© Kinexus Bioinformatics Corporation 2017